Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;56(4):1270-1276.
doi: 10.4143/crt.2023.1278. Epub 2024 Mar 6.

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer

Youngkyung Jeon  1 , Sehhoon Park  1 , Se-Hoon Lee  1 , Tae Hyuk Kim  2 , Sun Wook Kim  2 , Myung-Ju Ahn  1 , Hyun Ae Jung  1 , Jae Hoon Chung  2
Affiliations

Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer

Youngkyung Jeon et al. Cancer Res Treat. 2024 Oct.

Abstract

Purpose: BRAF mutations are detected in 30%-80% of papillary thyroid cancer (PTC) cases. DaBRAFenib and trametinib showed promising antitumor activity in patients with BRAFV600E-mutated metastatic melanoma and non-small cell lung cancer. This study aimed to evaluate the efficacy and safety of daBRAFenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer.

Materials and methods: This was a retrospective study to evaluate the efficacy of daBRAFenib and trametinib in patients with metastatic BRAFV600E-mutated PTC. The patients received daBRAFenib 150 mg twice daily and trametinib 2 mg once daily at the Samsung Medical Center. This study evaluated the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) overall survival (OS), and safety of daBRAFenib and trametinib.

Results: Between December 2019 and January 2022, 27 PTC patients including eight patients with poorly differentiated or anaplastic transformation, received daBRAFenib and trametinib. The median age was 73.0 years, and the median follow-up period was 19.8 months. The majority (81.5%) had undergone thyroidectomy, while 8 patients had received prior systemic treatments. ORR was 73.1%, with 19 partial responses, and DCR was 92.3%. Median PFS was 21.7 months, and median OS was 21.7 months. Treatment-related adverse events included generalized weakness (29.6%), fever (25.9%), and gastrointestinal problems (22.2%). Dose reduction due to adverse events was required in 81.5% of the patients.

Conclusion: DaBRAFenib and trametinib demonstrated a high ORR with promising PFS; however, most patients with BRAFV600E-mutated metastatic PTC required a dose reduction.

Keywords: BRAFV600E; Dabrafenib; Thyroid neoplasms; Trametinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

We are acknowledged for drug supply from Novartis.

Figures

Fig. 1.
Fig. 1.
Waterfall plot. PD, progressive disease; PR, partial response; SD, stable disease.
Fig. 2.
Fig. 2.
Kaplan-Meier curves for progression-free survival in all study population (A), lines of therapy (B), and histology (C). CI, confidence interval; P/D, poorly differentiated; PTC, papillary thyroid cancer.
Fig. 3.
Fig. 3.
Kaplan-Meier curves for overall survival in all study population (A), lines of therapy (B), and histology (C). CI, confidence interval; P/D, poorly differentiated; PTC, papillary thyroid cancer.
See this image and copyright information in PMC

References

    1. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 2021;9:225–34. - PubMed
    1. Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16:17–29. - PubMed
    1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–11. - PubMed
    1. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. Bethesda, MD: National Cancer Institute; 2018. SEER cancer statistics review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site [Internet] [cited 2023 Jan 30]. Available from: https://seer.cancer.gov/csr/1975_2015/
    1. Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045. - PubMed

MeSH terms

LinkOut - more resources